Study identifies blood molecule ACISOGA and colorectal cancer progression
- The study, published in the scientific journal Cancer Epidemiology, Biomarkers & Prevention, analyzed serum samples from 513 participants to evaluate biological indicators of colorectal cancer.
- Results from the initial cohort demonstrated a clear and constant upward trend in blood concentrations of the molecule.
- To strengthen their findings, the research team validated the discovery using an independent cohort of more than 1,100 participants from the European Prospective Investigation into Cancer and Nutrition...
Metabolomic Analysis Links ACISOGA to Tumor Progression
The study, published in the scientific journal Cancer Epidemiology, Biomarkers & Prevention, analyzed serum samples from 513 participants to evaluate biological indicators of colorectal cancer. The analysis identified ACISOGA—a molecule tied to polyamine metabolism—as the metabolite with the most consistent association with disease progression.
Results from the initial cohort demonstrated a clear and constant upward trend in blood concentrations of the molecule. Levels of ACISOGA increased progressively across distinct groups, rising from healthy individuals to patients with varying degrees of precancerous colorectal lesions and ultimately reaching the highest concentrations in patients diagnosed with colorectal cancer.
European Cohort Validates Link Between Metabolite and Tumorigenesis
To strengthen their findings, the research team validated the discovery using an independent cohort of more than 1,100 participants from the European Prospective Investigation into Cancer and Nutrition study. The investigators combined these metabolic datasets with genetic analyses to locate specific genomic regions associated with variations in ACISOGA levels.
By integrating metabolomic data, genetic findings, and external validation from a large European cohort, the researchers observed a consistent pattern connecting the metabolite to tumorigenesis.
Clinical Adoption Requires Further Investigation
Despite the strong statistical associations between blood metabolite levels and tumor growth, the study authors emphasize that clinical adoption requires further investigation. Mireia Obón-Santacana, the study’s principal author, highlighted the integration of independent evidence streams in published commentary. “Este estudio es especialmente relevante porque integra diferentes niveles de evidencia independiente -metabolómica, genética y validación externa en una gran cohorte europea— que apuntan en la misma dirección,” Obón-Santacana stated, pointing out that this coherence reinforces the biological mechanisms linking the molecule to disease advancement.
The investigative team concludes that ACISOGA functions as a promising circulating marker for future oncological studies. While current screening programs have improved detection rates, determining which specific lesions will advance into malignant tumors remains a primary challenge for biomedical research teams across the globe.